Medicare AdvantagePrior AuthMedium impact
Emrosi™ (minocycline) (Revised)
Humana·Dermatology, Internal Medicine, Infectious Disease·Medicare Advantage
We identified it
Jul 21, 2026
Summary
This is a revised Prior Authorization policy for Emrosi™ (minocycline) affecting Medicare Advantage members. The specific policy changes cannot be fully detailed as only a summary is available from the source document. Billing teams must obtain the complete policy document to identify what Prior Authorization requirements have changed and implement necessary workflow updates.
Action Required
Immediately: Billing team must access the complete policy document at https://dctm.humana.com/Mentor/Web/v.aspx?objectID=090009298a584808 to review the specific Prior Authorization requirements for Emrosi™ (minocycline). Once reviewed, update billing software and encounter forms to reflect the revised Prior Authorization criteria. Providers must be notified of any new or changed requirements. Ensure all claims submitted after the effective date comply with the revised policy to avoid denials. Flag this policy as superseding any previous Emrosi™ authorization guidance dated before this revision.